US 12,453,711 B2
Platinum complex anti-neoplastic agents comprising a cannabinoid ligand
Paul Hershberger, Miami, FL (US); and Philip Arlen, Miami, FL (US)
Assigned to Diverse Biotech, Inc., Orlando, FL (US)
Appl. No. 17/636,081
Filed by Diverse Biotech, Inc., Miami, FL (US)
PCT Filed Jun. 24, 2020, PCT No. PCT/US2020/039251
§ 371(c)(1), (2) Date Feb. 17, 2022,
PCT Pub. No. WO2021/034405, PCT Pub. Date Feb. 25, 2021.
Claims priority of provisional application 62/960,069, filed on Jan. 12, 2020.
Claims priority of provisional application 62/888,716, filed on Aug. 19, 2019.
Prior Publication US 2022/0288007 A1, Sep. 15, 2022
Int. Cl. A61K 31/282 (2006.01); A61K 31/05 (2006.01); A61K 31/555 (2006.01)
CPC A61K 31/282 (2013.01) [A61K 31/05 (2013.01); A61K 31/555 (2013.01)] 23 Claims
 
1. A platinum complex anti-neoplastic agent, comprising:
(a) a central platinum atom;
(b) a non-leaving ligand component selected from the group consisting of:
(i) a first non-leaving ligand and a second non-leaving ligand;
(ii) a first non-leaving ligand, a second non-leaving ligand, and a third non-leaving ligand;
(iii) a bidentate non-leaving ligand; and
(iv) a tridentate non-leaving ligand;
(c) a leaving ligand component selected from the group consisting of:
(i) a first leaving ligand, wherein the first leaving ligand is a first cannabinoid leaving ligand attached to the central platinum atom via a first oxygen atom of (1) a first hydroxy group of the first cannabinoid leaving ligand or (2) a first carboxyl group of the first cannabinoid leaving ligand;
(ii) a first leaving ligand and a second leaving ligand, wherein the first leaving ligand is the first cannabinoid leaving ligand; and
(iii) a bidentate leaving ligand, wherein the bidentate leaving ligand is the first cannabinoid leaving ligand attached to the central platinum atom via a first and a second oxygen atom independently selected from (1) an oxygen atom of a first hydroxy group of the first cannabinoid leaving ligand, (2) an oxygen atom of a second hydroxy group of the first cannabinoid leaving ligand, (3) an oxygen atom of a first carboxyl group of the first cannabinoid leaving ligand, and (4) an oxygen atom of a second carboxyl group of the first cannabinoid leaving ligand.